Cortex Discovery’s in silico drug discovery platform is based on its leading-edge AI technology which can predict molecule properties in all therapeutic fields. The accuracy of its predictions has been validated in the lab, and rivals that of experiments.

TechBio Founders #30:  Developing drug pipelines for life extension and age-related disorders with Ivan De Weber, CEO at Cortex Discovery

#TechBio is changing the world and the world needs to know more about it and the most disruptive companies who want to enable humanity to face up to its next challenges as a species, from fighting genetically transmitted diseases and pandemics to preventing ageing and climate change. In this podcast, we are featuring founders, investors, university professor or tech advisers sharing with us their unique view on the challenges and opportunities behind the Bioeconomy. This podcast is produced by Next Sequence, a venture capital fund focused on supporting globally the #TechBio ecosystem, from founders to investors.

Share TechBio Founders #30: Developing drug pipelines for life extension and age-related disorders with Ivan De Weber, CEO at Cortex Discovery

Sign up to save your podcasts

TechBio Founders #30: Developing drug pipelines for life extension and age-related disorders with Ivan De Weber, CEO at Cortex Discovery

TechBio Founders #30: Developing drug pipelines for life extension and age-related disorders with Ivan De Weber, CEO at Cortex Discovery